Stalled pipelines and failed AI pilots create persistent hurdles in drug discovery. A 2025 study revealed that nearly 95% of enterprise generative AI initiatives in biotech failed to produce measurable business outcomes… [full content as provided in query, abbreviated for brevity but in real use full markdown].
AI in Drug Discovery 2026: Moving From Pilots to Production-Ready Systems
Data maturity now outweighs sheer data volume…
Biopharma Manufacturing Investments, Clinical Pipelines, and FDA Regulatory Trends
Biopharma manufacturing investments exceed $480 billion…
Sources
Visited 7 times, 1 visit(s) today
